Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Breast Cancer
97%
Overall Survival
61%
Adverse Event
54%
Clinical Study
31%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
29%
Progression Free Survival
26%
Epidermal Growth Factor Receptor 2
24%
Gamma Urogastrone
24%
Atezolizumab
24%
Beta Adrenergic Receptor Blocking Agent
21%
Lapatinib
19%
Capecitabine
19%
Trastuzumab Emtansine
19%
Immunotherapy
18%
Malignant Neoplasm
15%
Neutropenia
14%
Diarrhea
14%
Lung Cancer
14%
Immune Checkpoint Inhibitor
14%
Naphthalimide Derivative
14%
Transitional Cell Carcinoma
14%
Nile Red
14%
Multiple Myeloma
14%
Thrombocytopenia
14%
Abemaciclib
14%
Antihypertensive Agent
14%
Anticoagulant Agent
14%
Effusion
14%
Anticancer Drug
14%
Antimicrobial Resistance
14%
Cross Sectional Study
12%
Adverse Outcome
9%
Pembrolizumab
9%
Nausea and Vomiting
7%
Nivolumab
7%
Pomalidomide
7%
Antibiotics
7%
Pertuzumab
6%
Trastuzumab
6%
Venous Thromboembolism
5%
Randomized Controlled Trial
5%
Cardiovascular Disease
5%
Medicine and Dentistry
Clinical Trial
80%
Medicine
62%
Patient-Reported Outcome
44%
Breast Cancer
44%
Clinical Study
39%
Overall Survival
31%
Adverse Event
28%
Atezolizumab
21%
Clinical Prediction Model
20%
Clinician
19%
Decision Making
16%
Pooled Analysis
16%
Thrombocytopenia
14%
Transitional Cell Carcinoma
14%
Lung Cancer
14%
Alertness
14%
Antithrombotic
14%
Multiple Myeloma
14%
Public Health
14%
Health Care
14%
Immunotherapy
14%
Anticancer Drug
14%
Oncology
12%
Progression Free Survival
12%
Immune Checkpoint Inhibitor
12%
Adverse Outcome
9%
Proportional Hazards Model
9%
Quality Improvement
9%
Immunity
8%
Lung
8%
Constipation
7%
Platelet
7%
Pharmacovigilance
7%
Vaping
7%
Patient Care
7%
Electrocorticography
6%
Prognostic Factor
6%
Meta-Analysis
6%
Venous Thromboembolism
5%
Loss of Appetite
5%
Cross Sectional Study
5%